Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV

Scott R. Evans, Thuy Tien T. Tran, Andrea M. Hujer, Carol B. Hill, Kristine M. Hujer, Jose R. Mediavilla, Claudia Manca, T. Nicholas Domitrovic, Federico Perez, Michael Farmer, Kelsey M. Pitzer, Brigid M. Wilson, Barry N. Kreiswirth, Robin Patel, Michael R. Jacobs, Liang Chen, Vance G. Fowler, Henry F. Chambers, Robert A. Bonomo

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background. Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa. Methods. In this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO). Results. We found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA). Conclusions. The diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.

Original languageEnglish (US)
Pages (from-to)1823-1830
Number of pages8
JournalClinical Infectious Diseases
Volume68
Issue number11
DOIs
StatePublished - May 17 2019

Keywords

  • Antimicrobial Resistance
  • Ceftazidime/Avibactam
  • Ceftolozane/Tazobactam
  • Pseudomonas Aeruginosa

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV'. Together they form a unique fingerprint.

  • Cite this

    Evans, S. R., Tran, T. T. T., Hujer, A. M., Hill, C. B., Hujer, K. M., Mediavilla, J. R., Manca, C., Domitrovic, T. N., Perez, F., Farmer, M., Pitzer, K. M., Wilson, B. M., Kreiswirth, B. N., Patel, R., Jacobs, M. R., Chen, L., Fowler, V. G., Chambers, H. F., & Bonomo, R. A. (2019). Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clinical Infectious Diseases, 68(11), 1823-1830. https://doi.org/10.1093/cid/ciy801